| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 康芝药业股份有限公司是主要从事儿童用药的研发、生产和销售的公司.公司生产经营5 种剂型11 个儿童药品种,涵盖了我国当前儿童用药中销量最大的解热镇痛类、感冒类、抗生素类、呼吸系统类、消食定惊类和营养类等六大类的西药和中成药.公司现生产和销售的自有儿童药产品主要包括瑞芝清(尼美舒利颗粒)、注射用头孢米诺钠、止咳橘红颗粒(国家二级中药保护品种)、感冒清热颗粒等品种.公司一直专注于儿童用药的生产研发,在儿童用药领域的研发及生产能力已处于国内领先地位."康芝"品牌中西药品深受广大患者的喜爱,儿科药品行销全国,康芝牌被评为"中国高新技术优秀品牌"。 | ||||||||||||||||||||||||
| Main Business | 以儿童药、婴童康护用品的研发生产与销售、生殖医学及妇儿健康医疗服务、医用口罩等医疗器械为主营业务的国内领先儿童大健康企业。 | ||||||||||||||||||||||||
| Legal Representative | 洪江游 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 林德新 | ||||||||||||||||||||||||
| Solicitors | 北京万商天勤律师事务所 | ||||||||||||||||||||||||
| Auditors | 中审国际会计师事务所有限公司 | ||||||||||||||||||||||||
| Tel No | 0898-66812876 | ||||||||||||||||||||||||
| Fax No | 0898-66812876 | ||||||||||||||||||||||||
| Website | www.honz.com.cn | ||||||||||||||||||||||||
| honz168@honz.com.cn | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 26/05/2010 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.026 | ||||||||||||||||||||||||
| DPS(RMB)* | -- | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 2.988 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 2.169B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |